DNLI Denali Therapeutics Inc

Price (delayed)

$66.80

Market cap

$8.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.22

Enterprise value

$7.73B

Sector: Healthcare
Industry: Biotechnology

Highlights

Denali Therapeutics's equity has surged by 101% YoY and by 76% QoQ
Denali Therapeutics's gross profit has shrunk by 84% YoY and by 15% QoQ
DNLI's revenue has dropped by 84% year-on-year and by 15% since the previous quarter

Key stats

What are the main financial stats of DNLI
Market
Shares outstanding
119.92M
Market cap
$8.01B
Enterprise value
$7.73B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.02
Price to sales (P/S)
305.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
328.69
Earnings
Revenue
$23.52M
EBIT
-$227.7M
EBITDA
-$218.37M
Free cash flow
-$150.08M
Per share
EPS
-$2.22
Free cash flow per share
-$1.4
Book value per share
$8.33
Revenue per share
$0.22
TBVPS
$9.96
Balance sheet
Total assets
$1.07B
Total liabilities
$187.76M
Debt
$69.92M
Equity
$882.55M
Working capital
$865.45M
Liquidity
Debt to equity
0.08
Current ratio
9.21
Quick ratio
9.12
Net debt/EBITDA
1.29
Margins
EBITDA margin
-928.6%
Gross margin
100%
Net margin
-968.6%
Operating margin
-1,016.8%
Efficiency
Return on assets
-30.7%
Return on equity
-39.2%
Return on invested capital
-41%
Return on capital employed
-23.6%
Return on sales
-968.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNLI stock price

How has the Denali Therapeutics stock price performed over time
Intraday
3.33%
1 week
6.35%
1 month
-15.58%
1 year
194.4%
YTD
-20.25%
QTD
-20.25%

Financial performance

How have Denali Therapeutics's revenue and profit performed over time
Revenue
$23.52M
Gross profit
$23.52M
Operating income
-$239.12M
Net income
-$227.77M
Gross margin
100%
Net margin
-968.6%
DNLI's operating income has dropped by 196% year-on-year and by 4.3% since the previous quarter
Denali Therapeutics's gross profit has shrunk by 84% YoY and by 15% QoQ
DNLI's revenue has dropped by 84% year-on-year and by 15% since the previous quarter
Denali Therapeutics's net margin has decreased by 24% from the previous quarter

Growth

What is Denali Therapeutics's growth rate over time

Valuation

What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
8.02
P/S
305.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
328.69
The EPS has decreased by 2.8% from the previous quarter
Denali Therapeutics's equity has surged by 101% YoY and by 76% QoQ
DNLI's price to book (P/B) is 87% more than its last 4 quarters average of 4.3
DNLI's revenue has dropped by 84% year-on-year and by 15% since the previous quarter

Efficiency

How efficient is Denali Therapeutics business performance
The return on equity has dropped by 193% year-on-year but it has increased by 15% since the previous quarter
The ROS has decreased by 24% from the previous quarter
The return on assets has increased by 11% since the previous quarter

Dividends

What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNLI.

Financial health

How did Denali Therapeutics financials performed over time
The company's total assets has surged by 78% YoY and by 65% QoQ
DNLI's total liabilities is up by 29% since the previous quarter and by 14% year-on-year
Denali Therapeutics's debt is 92% less than its equity
Denali Therapeutics's equity has surged by 101% YoY and by 76% QoQ
DNLI's debt to equity has dropped by 50% year-on-year and by 43% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.